iMed Technologies
This company develops software to assist in neurovascular surgery using deep learning.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | $1.6m | Series B | |
| Total Funding | 000k | ||
iMed Technologies, a company established in 2019, is focused on developing artificial intelligence to support surgeons in real-time during neuroendovascular therapy. The firm was co-founded by Dr. Kenichi Kono (CEO) and Motohisa Kaneko (COO).
Dr. Kono's journey to founding the company stems from his 16 years of experience as a neurosurgeon. During his extensive career, he directly witnessed the challenges and complexities of neuroendovascular surgery, a minimally invasive procedure for treating conditions like cerebral infarctions and subarachnoid hemorrhages. Recognizing the need to reduce reliance on individual surgeon skill and improve safety, he pursued an MBA at GLOBIS University, where he cultivated his vision for the company. His background in both medicine, with a Doctor of Medicine from Kyoto University, and mathematics from The University of Tokyo, provided a unique foundation for this venture. Mr. Kaneko complements this with his experience in strategic consulting, M&A advisory for the IT and healthcare sectors, and private equity investment.
The company's core business revolves around the development and sale of its medical imaging analysis software, "Neuro-Vascular Assist". This system analyzes images from angiography equipment during surgery to assist with the intricate maneuvers required. It provides real-time alerts to the surgeon, for example, by notifying them if a medical device crosses a pre-set boundary, helping to prevent complications that can arise from minute operational delays or deviations. The platform is designed not only to support experienced surgeons but also to serve as an educational tool for younger doctors. The market for neuroendovascular therapy is expanding, with procedure volumes increasing by over 10% annually due to its less invasive nature compared to traditional open-skull surgery. iMed Technologies operates on a B2B model, providing its software to hospitals and medical institutions. The company has received funding from investors including SBI Investment, Mitsui Sumitomo Insurance Venture Capital, and the GLOBIS Alumni Growth Investment (G-GROWTH) program.
Keywords: surgical support AI, neuroendovascular therapy, medical imaging analysis, real-time surgical assistance, cerebral infarction treatment, subarachnoid hemorrhage surgery, deep learning in healthcare, medical device technology, MedTech, neurosurgery, surgical safety, physician support tool, angiography analysis, catheter surgery, minimally invasive surgery, clinical decision support, healthcare AI, Neuro-Vascular Assist, Kenichi Kono, neuroradiology